BIIB
BIOGEN INC.
Key Financials
Gross Profit
$11.6B
↑ 392.8%
Net Income
$1.3B
↓ 20.8%
Revenue
$9.9B
↑ 2.2%
Operating Income
$2.8B
↓ 37.6%
EPS (Diluted)
$8.79
↓ 21.4%
Long-term Debt
$6.3B
↓ 0.1%
Total Liabilities
$11.2B
↓ 1.3%
Total Assets
$29.4B
↑ 5.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13D/A | 5/14/2026 | View on SEC |
| 8-K | 5/14/2026 | View on SEC |
| SC TO-T/A | 5/14/2026 | View on SEC |
| SC TO-T/A | 5/12/2026 | View on SEC |
| SC TO-T/A | 5/6/2026 | View on SEC |
| SCHEDULE 13G/A | 5/6/2026 | View on SEC |
| 4 | 5/5/2026 | View on SEC |
| SCHEDULE 13G | 4/29/2026 | View on SEC |
| 10-Q | 4/29/2026 | View on SEC |
| 8-K | 4/29/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | BIIB |
| Company Name | BIOGEN INC. |
| CIK | 875045 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 6176792000 |